Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Marinus Pharma CS (NQ: MRNS ) 1.410 +0.010 (+0.71%) Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,365,206 Open 1.420 Bid (Size) 1.400 (7) Ask (Size) 1.410 (8) Prev. Close 1.400 Today's Range 1.390 - 1.430 52wk Range 1.120 - 11.26 Shares Outstanding 54,642,580 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News How Is The Market Feeling About Marinus Pharma? April 29, 2024 Via Benzinga Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday April 17, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Performance YTD -86.44% -86.44% 1 Month -84.28% -84.28% 3 Month -85.89% -85.89% 6 Month -79.68% -79.68% 1 Year -84.55% -84.55% More News Read More Analysts Question Commercial Viability of Marinus' IV Ganaxolone After Interim Analysis Miss April 16, 2024 Via Benzinga The Latest Analyst Ratings For Marinus Pharma April 16, 2024 Via Benzinga S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March April 15, 2024 Via Benzinga Topics Stocks Exposures US Equities Peeling Back The Layers: Exploring Marinus Pharma Through Analyst Insights March 26, 2024 Via Benzinga Leverage Shares -3x Short Moderna (MRNA) ETP Securities: Q4 Earnings Insights March 05, 2024 Via Benzinga Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session April 15, 2024 Via Benzinga Biotech on a Budget: 7 Stocks Under $10 With Huge Potential April 15, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Monday's Intraday Session April 15, 2024 Via Benzinga Why Are Stocks Up Today? April 15, 2024 Via InvestorPlace Crude Oil Down 1%; Charles Schwab Sales Top Estimates April 15, 2024 Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities DJT Stock Alert: Trump Media Plunges on Share Sale Panic April 15, 2024 Via InvestorPlace Topics Government Exposures Political Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today? April 15, 2024 Via InvestorPlace INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm April 15, 2024 From Schall Law Via GlobeNewswire Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday? April 15, 2024 Via Benzinga Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings April 15, 2024 Via Benzinga Topics Stocks Exposures US Equities Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session April 15, 2024 Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Monday's Pre-Market Session April 15, 2024 Via Benzinga Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results April 15, 2024 From Marinus Pharmaceuticals Via Business Wire Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) April 05, 2024 From Marinus Pharmaceuticals Via Business Wire Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review March 27, 2024 From Marinus Pharmaceuticals Via Business Wire MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q4 2023 March 05, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Tuesday's After-Market Session March 05, 2024 Via Benzinga Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results March 05, 2024 From Marinus Pharmaceuticals Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
